Evidence map›Paper›PMID 42388583›Full record

ReviewCancer diagnosis & prognosis

Diagnostic and Prognostic Applications of PET/CT in Small-cell Lung Cancer.

Yukinori Okada, Tatsuhiko Zama, Tomohiro Itonaga, Ryuji Mikami, Mitsuru Okubo, Shinji Sugahara, Shiho Wada, Tsubasa Kawamoto, Yui Mabuchi, Masumi Kawaguchi and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yukinori OkadaDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Tatsuhiko ZamaDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Tomohiro ItonagaDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Ryuji MikamiDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Mitsuru OkuboDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Shinji SugaharaDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Shiho WadaDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Tsubasa KawamotoDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Yui MabuchiDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Masumi KawaguchiDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Masanori IshidaDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Motoki NakaiDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Koichiro AbeDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Mana YoshimuraDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.
Kazuhiro SaitoDepartment of Radiology, Tokyo Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: In small-cell lung cancer, treatment differs between extensive disease (ED) and limited disease (LD). Chemotherapy plus immune checkpoint inhibitors is used in patients with ED. In patients with LD, chemoradiotherapy or chemoradiotherapy plus immune checkpoint inhibitors is used. Therefore, initial staging is important. Some reports exist on the utility of positron emission tomography-computed tomography (PET/CT); in particular, PET/CT can change the diagnosis between LD and ED. This review aimed to summarize the utility of PET/CT in small-cell lung cancer. Materials and Methods: We identified relevant articles published on PUBMED between 2010 and 2025 using selected keywords. We categorized the contents into disease staging, prognosis prediction, and topics, and then summarized section-by-section. Results: In addition to cancer staging between ED and LD, PET/CT can be used to evaluate semiquantitative indicators such as the maximum standard uptake value (SUVmax), total lesion glycolysis (TLG), and metabolic tumor volume (MTV). This is important as SUVmax, TLG, and MTV have been shown to predict treatment response. Conclusion: PET/CT is useful for staging small-cell lung cancers. However, reports on its usefulness for prognostic prediction are mixed, with some finding it useful and others not. Further research is needed as treatment approaches for small-cell lung cancer are evolving.

Indexed as

maximum standardized uptake valuemetabolic tumor volumepositron emission tomography-computed tomography imagingreviewSmall-cell lung cancertotal lesion glycolysis

Identifiers

PMID42388583
PMCPMC13321951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.